Labetalol - NDSRI's
References
FAQ's
References
- Gold, Elijah H.; Chang, Wei; Cohen, Marvin; Baum, Thomas; Ehrreich, Stewart; Johnson, Gordon; Prioli, Nicholas; Sybertz, Edmund J., Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol, Journal of Medicinal Chemistry Volume: 25, Issue: 11, Pages: 1363-70, 1982
- Dusci, L. J.; Hackett, L. P., Determination of labetalol in human plasma by high-performance liquid chromatography, Journal of Chromatography, Volume: 175, Issue: 1, Pages: 208-10, 1979
Frequently Asked Questions
Is it possible to eliminate Labetalol impurities from the drug?
It is impossible to eliminate all impurities from the drug. However, manufacturers strive to minimize impurity levels within acceptable limits defined by regulatory authorities.
How can impurity-related issues with Labetalol be resolved?
Addressing impurity-related issues with Labetalol may involve process optimization, modification of synthetic routes, or introduction of additional purification steps.
Which solvent helps in analyzing Labetalol impurities?
Methanol or DMSO is commonly used as a solvent when analyzing many impurities in Labetalol.
How should Labetalol impurities be stored in terms of temperature?
The recommendation is to store Labetalol impurities at a controlled room temperature, within 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.